Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication – Modified Dosing Recommendations

Audience: Nephrology, Oncology Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp)
ISSUE: FDA notified healthcare professionals that new, modified recommendations for more conservative dosing of…

Angiotensin Receptor Blockers (ARBs): Drug Safety Communication – Drug Safety Review Completed Audience: Cardiology, Oncology, Family Practice [UPDATED 06/02/2011] FDA’s meta-analysis of...

FREE Case Review

Defective DrugsAdverse reactions to medications on the market.

Personal InjuryPersonal injuries resulting from negligence may lead to significant medical expenses.

Toxic ExposureDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

DiseasesDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

Financial FraudsUnethical actions by large corporations may cause financial hardship.

Medical MalpracticeMedical errors or negligent health care resulting in injury or death.

Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication – Modified Dosing Recommendations

FREE Case Review

Trending Topics